Pictet Asset Management
DAWN

Pictet Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Pictet Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,034
Closed -$279K – 2163
2026
Q1 		$279K Sell
13,034
-2,977,767
-100% -$42M ﹤0.01% 1750
2025
Q4 		$27.9M Buy
2,990,801
+617,668
+26% +$5.16M 0.03% 446
2025
Q3 		$16.7M Sell
2,373,133
-1,349,599
-36% -$9.29M 0.02% 559
2025
Q2 		$24.2M Buy
3,722,732
+87,152
+2% +$600K 0.02% 465
2025
Q1 		$28.8M Buy
3,635,580
+145,516
+4% +$1.57M 0.03% 411
2024
Q4 		$44.2M Buy
3,490,064
+507,398
+17% +$7.06M 0.05% 325
2024
Q3 		$41.5M Buy
2,982,666
+131,092
+5% +$1.87M 0.05% 331
2024
Q2 		$39.3M Buy
2,851,574
+476,437
+20% +$6.97M 0.05% 325
2024
Q1 		$39.2M Sell
2,375,137
-196,431
-8% -$2.94M 0.04% 359
2023
Q4 		$37.5M Buy
2,571,568
+1,971,529
+329% +$23.9M 0.04% 356
2023
Q3 		$7.36M Buy
+600,039
New +$7.83M 0.01% 681

Other funds holding DAWN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Pictet Asset Management's DAWN Position: Q2 2026 in Review

Pictet Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 13,034 shares — an estimated $279K sold.

Pictet Asset Management first reported a position in DAWN in Q3 2023 and held it in 11 quarters. The position peaked at $44.2M in Q4 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

  • Pictet Asset Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Pictet Asset Management sold 13,034 Day One Biopharmaceuticals shares in Q2 2026, an estimated $279K.
  • Pictet Asset Management first reported a position in Day One Biopharmaceuticals in Q3 2023 and held it in 11 quarters.
  • Pictet Asset Management's Day One Biopharmaceuticals position peaked at $44.2M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.